{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T21:10:07Z","timestamp":1770325807584,"version":"3.49.0"},"reference-count":21,"publisher":"Elsevier BV","issue":"1-3","license":[{"start":{"date-parts":[[2014,3,1]],"date-time":"2014-03-01T00:00:00Z","timestamp":1393632000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","schres-journal.com","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Schizophrenia Research"],"published-print":{"date-parts":[[2014,3]]},"DOI":"10.1016\/j.schres.2013.11.042","type":"journal-article","created":{"date-parts":[[2014,2,12]],"date-time":"2014-02-12T06:45:55Z","timestamp":1392187555000},"page":"160-168","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["A trial evaluating gradual- or immediate-switch strategies from risperidone, olanzapine, or aripiprazole to iloperidone in patients with schizophrenia"],"prefix":"10.1016","volume":"153","author":[{"given":"Peter J.","family":"Weiden","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leslie","family":"Citrome","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gus","family":"Alva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew","family":"Brams","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ira D.","family":"Glick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2078-807X","authenticated-orcid":false,"given":"Richard","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Greg","family":"Mattingly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Farid","family":"Kianifard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiangyi","family":"Meng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linda","family":"Pestreich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marla","family":"Hochfeld","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam","family":"Winseck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.schres.2013.11.042_bb0005","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.4088\/JCP.09m05785yel","article-title":"An algorithm-based approach to first-episode schizophrenia: response rates over 3 prospective antipsychotics trials with a retrospective data analysis","volume":"72","author":"Agid","year":"2011","journal-title":"J. Clin. Psychiatry."},{"key":"10.1016\/j.schres.2013.11.042_bb0010","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1477-7525-2-12","article-title":"Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease","volume":"2","author":"Atkinson","year":"2004","journal-title":"Health. Qual. Life. Outcomes."},{"key":"10.1016\/j.schres.2013.11.042_bb0015","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s00213-002-1344-3","article-title":"Switching patients to aripiprazole from other antipsychotic agents: a multicenter randomized study","volume":"166","author":"Casey","year":"2003","journal-title":"Psychopharmacology (Berl.)."},{"key":"10.1016\/j.schres.2013.11.042_bb0020","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1517\/14656566.2012.656590","article-title":"Treatment-emergent adverse events associated with atypical antipsychotics","volume":"13","author":"Cha","year":"2012","journal-title":"Expert. Opin. Pharmacother."},{"issue":"2 Suppl. 1","key":"10.1016\/j.schres.2013.11.042_bb0025","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1097\/JCP.0b013e318169d4ce","article-title":"Four-week, double-blind, placebo- and ziprasidone-controlled trial of iloperidone in patients with acute exacerbations of schizophrenia","volume":"28","author":"Cutler","year":"2008","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.schres.2013.11.042_bb0030","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.1176\/appi.ajp.163.12.2090","article-title":"Effectiveness of switching antipsychotic medications","volume":"163","author":"Essock","year":"2006","journal-title":"Am. J. Psychiatry."},{"key":"10.1016\/j.schres.2013.11.042_bb0035","unstructured":"Fanapt (iloperidone) Prescribing Information, 2013. East Hanover, NJ, Novartis Pharmaceuticals Corporation."},{"key":"10.1016\/j.schres.2013.11.042_bb0040","series-title":"ECDEU Assessment Manual for Psychopharmacology, Revised","first-page":"218","article-title":"CGI clinical global impressions","author":"Guy","year":"1976"},{"key":"10.1016\/j.schres.2013.11.042_bb0045","doi-asserted-by":"crossref","first-page":"S29","DOI":"10.1097\/JCP.0b013e318169cca7","article-title":"Long-term efficacy and safety of iloperidone: results from 3 clinical trials for the treatment of schizophrenia","volume":"28","author":"Kane","year":"2008","journal-title":"J. Clin. Psychopharmacol."},{"issue":"Suppl. 7\u201314","key":"10.1016\/j.schres.2013.11.042_bb0050","article-title":"Definitions of response and remission in schizophrenia: recommendations for their use and their presentation","author":"Leucht","year":"2009","journal-title":"Acta. Psychiatr. Scand."},{"key":"10.1016\/j.schres.2013.11.042_bb0055","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1038\/sj.npp.1300873","article-title":"The relative sensitivity of the Clinical Global Impressions Scale and the Brief Psychiatric Rating Scale in antipsychotic drug trials","volume":"31","author":"Leucht","year":"2006","journal-title":"Neuropsychopharmacology."},{"key":"10.1016\/j.schres.2013.11.042_bb0060","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.schres.2007.09.006","article-title":"Extrapolation between measures of symptom severity and change: an examination of the PANSS and CGI","volume":"98","author":"Levine","year":"2008","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2013.11.042_bb0065","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1056\/NEJMoa051688","article-title":"Effectiveness of antipsychotic drugs in patients with chronic schizophrenia","volume":"353","author":"Lieberman","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.schres.2013.11.042_bb0070","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1192\/bjp.bp.111.101485","article-title":"Extrapyramidal motor side-effects of first- and second-generation antipsychotic drugs","volume":"200","author":"Peluso","year":"2012","journal-title":"Br. J. Psychiatry."},{"issue":"Suppl. 1","key":"10.1016\/j.schres.2013.11.042_bb0075","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1097\/JCP.0b013e3181692787","article-title":"Efficacy of iloperidone in the treatment of schizophrenia: initial phase 3 studies","volume":"28","author":"Potkin","year":"2008","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.schres.2013.11.042_bb0080","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0024-3205(00)00911-5","article-title":"Binding of antipsychotic drugs to human brain receptors: focus on newer generation compounds","volume":"68","author":"Richelson","year":"2000","journal-title":"Life. Sci."},{"key":"10.1016\/j.schres.2013.11.042_bb0085","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/hup.2247","article-title":"A global measure to assess switching antipsychotic medications in the treatment of schizophrenia","volume":"27","author":"Targum","year":"2012","journal-title":"Hum. Psychopharmacol."},{"key":"10.1016\/j.schres.2013.11.042_bb0090","doi-asserted-by":"crossref","first-page":"34","DOI":"10.3371\/CSRP.6.1.5","article-title":"Iloperidone for the treatment of schizophrenia: an updated clinical review","volume":"6","author":"Weiden","year":"2012","journal-title":"Clin. Schizophr. Relat. Psychoses."},{"issue":"2 Suppl. 1","key":"10.1016\/j.schres.2013.11.042_bb0095","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1097\/JCP.0b013e3181694f5a","article-title":"Safety profile of iloperidone: a pooled analysis of 6-week acute-phase pivotal trials","volume":"28","author":"Weiden","year":"2008","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.schres.2013.11.042_bb0100","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1097\/01.jcp.0000095347.32154.08","article-title":"Improvement in indices of health status in outpatients with schizophrenia switched to ziprasidone","volume":"23","author":"Weiden","year":"2003","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.schres.2013.11.042_bb0105","doi-asserted-by":"crossref","first-page":"580","DOI":"10.4088\/JCP.v64n0514","article-title":"Effectiveness of switching to ziprasidone for stable but symptomatic outpatients with schizophrenia","volume":"64","author":"Weiden","year":"2003","journal-title":"J. Clin. Psychiatry."}],"container-title":["Schizophrenia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996413006592?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996413006592?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,6]],"date-time":"2018-10-06T14:27:22Z","timestamp":1538836042000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920996413006592"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3]]},"references-count":21,"journal-issue":{"issue":"1-3","published-print":{"date-parts":[[2014,3]]}},"alternative-id":["S0920996413006592"],"URL":"https:\/\/doi.org\/10.1016\/j.schres.2013.11.042","relation":{},"ISSN":["0920-9964"],"issn-type":[{"value":"0920-9964","type":"print"}],"subject":[],"published":{"date-parts":[[2014,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A trial evaluating gradual- or immediate-switch strategies from risperidone, olanzapine, or aripiprazole to iloperidone in patients with schizophrenia","name":"articletitle","label":"Article Title"},{"value":"Schizophrenia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.schres.2013.11.042","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}